CK7和CK19蛋白在原发性肝癌中的表达和意义

doi:10.3969/j.issn.1004-616x.2026.02.008

Abstract

Abstract: OBJECTIVE: To investigate expressions of cytokeratin 7（CK7） and cytokeratin 19（CK19） in primary liver cancer and to analyze their clinical significance. METHODS: Immunohistochemical Envision method was used to detect expression of cytokeratins in cancer tissues from 56 liver cancer patients. Spearman correlation was used to calculate the correlation coefficient between cytokeratins. The chi-square test or Fisher's exact probability test was used to analyze relationships between expression of CK7 and CK19 proteins and clinicopathological characteristics of patients. ROC curve was used to analyze accuracy of CK7 and CK19 protein expression levels in predicting the survival status of patients. Kaplan-Meier method was used to calculate survival rates of patients,and the Log-rank test was performed. RESULTS: The positive expression rates of CK7, CK8, CK18, CK19, and CK20 proteins in liver cancer tissues were 30.36%, 89.29%,69.64%,21.43%,and 5.36%,respectively. The expression levels of CK7 and CK19 proteins were positively correlated（r=0.602,P=0.00）. In primary liver cancer, expression of CK7 protein was related to the degree of differentiation and pathological type of liver cancer tissue（χ²=8.155,12.118,respectively,P<0.05）. Expression of CK19 protein was related to tumor diameter,tissue differentiation,tumor stage,and pathological type（χ²=7.263,15.955,7.292,10.672,respectively,all P<0.05）. Prognostic analysis showed that the area under the receiver operating characteristic（ROC） curve for CK7 protein in predicting the survival status of patients was0.750,with a standard error of 0.210 and a 95% confidence interval of（0.338,1.000）. The area under the ROC curve for CK19 was 0.875,with a standard error of 0.155 and a 95% confidence interval of（0.571,1.000）. CK8, CK18, and CK20 showed low predictive accuracy for patient survival status. Survival analysis results showed that CK7 and CK19 had no significant effect on the survival time of patients（P>0.05）. CONCLUSION: Expressions of CK7 and CK19 were highly and positively correlated. Both CK7 and CK19 affected tissue differentiation and pathological type of liver cancer patients. Prognostic analysis showed that expression of CK7 and CK19 had good prediction on postoperative survival status of patients. However,survival analysis showed that they have no significant effect on postoperative survival time of patients.

Key words: cancer, primary liver cancer, cytokeratin, prognosis of liver cancer

CLC Number:

R730.2

GUO Feiyu, HU Hao, JING Fa, LI Wei. Significance of CK7 and CK19 expressions in primary liver cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(2): 137-141.

References

[1] WANG M, ZHOU J M, ZHANG L, et al. Surgical treatment of ovarian cancer liver metastasis[J]. Hepatobiliary Surg Nutr,2019, 8(2):129-137.
[2] 刘鑫苗,高红军,康艳,等.胞质多聚腺苷酸结合蛋白4在肝癌中的表达及其功能[J].癌变·畸变·突变, 2025, 37(3):209-214, 220.
[3] WANG W H, SMITS R, HAO H P, et al. Wnt/β-catenin signaling in liver cancers[J]. Cancers, 2019, 11(7):926.
[4] 周旻,杨冬华,汤绍辉,等.肝癌组织细胞角蛋白7、19表达的评估[J].中国病理生理杂志, 2006, 22(10):2064-2065, 2073.
[5] SUKSWAI N, KHOURY J D. Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection[J]. Curr Hematol Malig Rep, 2019, 14(5):368-375.
[6] BADVE S S, FISHER C. AJCC 8(th)edition-a step forward[J].Breast J, 2020, 26(7):1263-1264.
[7] 朱文标,闫春梅,丘波,等.分泌型卷曲相关蛋白4在肝细胞癌中的表达及其与患者临床病理指标和预后的关系[J].癌变·畸变·突变, 2024, 36(4):288-293, 297.
[8] ZHUO J Y, LU D, TAN W Y, et al. CK19-positive hepatocellular carcinoma is a characteristic subtype[J]. J Cancer, 2020, 11(17):5069-5077.
[9] PARK J H, KIM J H. Pathologic differential diagnosis of metastatic carcinoma in the liver[J]. Clin Mol Hepatol, 2019, 25(1):12-20.
[10] NG K L, ELLIS R J, SAMARATUNGA H, et al. Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma[J]. Transl Androl Urol, 2019, 8(Sup 2):123-137.
[11] MEHRPOUYA M, POURHASHEM Z, YARDEHNAVI N, et al. Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods[J].J Cell Physiol, 2019, 234(12):21425-21435.
[12] MORALES S, VELASCO A, GASOL A, et al. Circulating tumor cells(CTCs)and cytokeratin 19(CK19)mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer[J]. Cancer Treat Res Commun, 2018, 16:13-17.
[13] OZSEN M, ADIM S B, AKYILDIZ E U, et al. The role of immunohistochemical staining with CK7 in the differential diagnosis of autoimmune hepatitis[J]. Bratisl Lek Listy, 2019,120(11):839-842.
[14] YANG Z Y, ZHANG H Y, WANG F, et al. Expression of cytokeratin(CK)7, CK8/18, CK19 and p40 in esophageal squamous cell carcinoma and their correlation with prognosis[J]. Chin J Pathol, 2018, 47(11):834-839.
[15] BONACHO T, RODRIGUES F, LIBERAL J. Immunohistochemistry for diagnosis and prognosis of breast cancer:a review[J]. Biotech Histochem, 2020, 95(2):71-91.
[16] SOETA K, IUCHI K, HISATOMI H, et al. Generation of rat monoclonal antibody for cytokeratin 18 by immunization of three-dimensional-cultured cancer cells[J]. Monoclon Antib Immunodiagn Immunother, 2020, 39(6):199-203.
[17] CHENG Y, QIN K, HUANG N, et al. Cytokeratin 18 regulates the transcription and alternative splicing of apoptotic-related genes and pathways in HeLa cells[J]. Oncol Rep, 2019, 42(1):301-312.
[18] SHANG G G, JIN Y, ZHENG Q, et al. Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese[J]. Am J Cancer Res, 2019, 9(6):1212-1223.

Significance of CK7 and CK19 expressions in primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YANG Yongkang, LU Xinqi, ZHOU Li. A machine learning model integrating contrast-enhanced CT radiomics and clinical features for predicting lymph node metastasis in cervical squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(2): 119-127,136.
[2]	JI Jiayin, LUO Mengyu, LI Hongxia, ZHONG Zhaoyue, KANG Ling. Effect of autophagy on ferroptosis in colon cancer cells treated with the combination of 5-fluorouracil and oxaliplatin [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(1): 7-14.
[3]	CAI Xiaotong, XIE Bingmeng, ZHOU Li, LI Yangkang, HUANG Yiteng, PENG Lin. Correlation analysis of inflammation-nutrition composite indexes with prognosis of type I endometrial cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(1): 15-21.
[4]	YIN Lu, ZHANG Zhiliang, ZHANG Lin, YE Lan. Usefulness of thin-prep cytologic test combined with high-risk human papilloma virus detection in opportunistic screening for cervical cancer in postmenopausal women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(1): 22-26.
[5]	ZHAO Hongzheng, YE Yiliang, MA Ming. Significance of systemic immunoinflammatory index in clinical diagnosis and progression monitoring on patients with non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 369-374.
[6]	LI Jiarong, LIN Junhao, QIU Zhaolong, ZHU Zhiqin, CHEN Fengsheng. Expression and prognostic value of CDS1 in breast cancer based on pan-cancer analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 375-382.
[7]	LI Yanyang, SUN Lingling, CAI Xiaojun, XIE Yalin, SU Shan, CEN Wenchang, LI Chaoxia, LI Libo, SU Ning. Inhibitory effects of photodynamic therapy on cervical cancer cell lines with different Ki-67 expression levels [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 383-388.
[8]	LIU Jiabo, LIN Hua, CUI Beiyi, SUN Huixin. Trends in incidence and mortality of colorectal cancer in China: based on age-period-cohort model [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 393-399.
[9]	YANG Zhihui, HAN Xianglong, LIU Gengang, SHI Jie. Relationships between serum Lipocalin-2 and YKL-40 levels on therapeutic effect of neoadjuvant radiotherapy and chemotherapy in esophageal cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 310-313,318.
[10]	AYIGULI·Hare, ABUDILI·Abuduxuku. Expression of SATB1 and PRKDC proteins and sensitivity of advanced esophageal squamous cell carcinomas to chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 314-318.
[11]	LIU Xinmiao, GAO Hongjun, KANG Yan, ZHANG Yun, SUN Yulin. Expression and function of PABPC4 in liver cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 209-214,220.
[12]	CUI Ying, ZHAO Linlin, YU Jing, ZHAO Huan, ZHANG Zhihui, GUO Huiqin. Efficacy of cytopathological examination using serous effusion in the diagnosis of high-grade ovarian serous carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 228-233,251.
[13]	HOU Huiyun, BAI Feihu, YAN Xi, WU Lihong, ZUO Pengxi, WANG Jun. Correlations between COL5A2 protein expression and clinicopathological parameters in patients with gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 242-247.
[14]	YU Pingyang, LI Jinyang, DOU He, XIAO Min. Glycyrrhizic acid reduces paclitaxel resistance in triple-negative breast cancer by inhibiting the OGT-MDH1 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 33-38.
[15]	Lü Jie, CHEN Zhonghua, WANG Bo. The role of circular RNA homeodomain interacting protein kinase 3 in triple-negative breast cancer cell invasion [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 39-44,51.